Abstract Library

#4466 Molecular characterisation of extrapulmonary mixed adeno-neuroendocrine neoplasms (MiNENs): The NIRVANA sub study

Introduction: Extrapulmonary (EP) mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) are rare cancers with a dismal prognosis. The gene mutation profiles are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: MiNEN, NGS, ESCAT, chemotherapy,

#3963 Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

Introduction: NEN consist of a heterogeneous group of rare tumors. For these patients, clinical trials requiring a high number of patients are often infeasible. Often, the prognosis is poor due to late diagnosis and fewer available treatment options as compared to patients with common cancer types. In common cancers, ultrasensitive molecular profiling of circulating cell-free DNA (USccfDNA) based tests are promising to improve diagnosis, detection of minimal residual disease (MRD), and recurrence. Data needed to apply USccfDNA in NEN is lacking.

Conference:

Presenting Author:

Authors: de Hosson L, Pieterman C, Fehrmann R, de Herder W, Jalving M,

Keywords: circulating cell free DNA, biobank, databank, early detection,

#3546 Neuroendocrine tumors, experience at Instituto Nacional de Enfermedades Neoplasicas in a hospital from Peru

Introduction: Neuroendocrine tumors (NETs) are very rare cancers with indolent behavior, diagnosis is a challenge because of inespecific symptoms, treatments are in development and prognosis is variable.

Conference:

Presenting Author: Paitan V

Authors: Paitan V, Leonardo A, Bravo J, Taxa L, Castro V,

Keywords: Neuroendocrine tumor, Incidence, survival,

#3536 Comparison of drug sensitivity profiles of various NEN spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.

Conference:

Presenting Author: Ear P

Authors: Tran C, Luis B, Sherman S, Mudd J, Abusada E,

Keywords: NET, NEC, spheroid, drug screening, PDX model,

#3398 Patient-derived tumoroids phenocopy original gastro-entero-pancreatic neuroendocrine neoplasms and facilitate in vitro drug screening

Introduction: GastroEnteroPancreatic Neuroendocrine Neoplasms (GEP-NENs) are rare cancers that appear clinically and biologically extremely heterogenous. While highly proliferative cases are invariably lethal, slower-proliferating NENs—representing predominant cases—have unpredictable clinical courses varying from indolent to malignant. Recent comprehensive NGS screens in patients helped to extend our understanding. However, complementary relevant preclinical models to address disease heterogeneity and to investigate patient-specific treatment alternatives are still inexistent.

Conference:

Presenting Author: April-Monn S

Authors: April-Monn S, Kirchner P, Detjen K, Gloor B, Partelli S,

Keywords: GEP-NEN, Organoid, Tumoroid, Model, Drug screening, translational, single-cell RNAseq, NGS, OMICs, biomarker,